[HTML][HTML] The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19

MA Almadhi, A Abdulrahman, SA Sharaf… - International journal of …, 2021 - Elsevier
Purpose The COVID-19 pandemic has led to over 92 million cases and 1.9 million deaths
worldwide since its outbreak. Public health responses have focused on identifying …

[HTML][HTML] The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes

MA Almadhi, A Abdulrahman, A Alawadhi… - Scientific reports, 2021 - nature.com
The COVID-19 pandemic has affected more than 100 million cases and caused immense
burdens on governments and healthcare systems worldwide. Since its emergence in …

[HTML][HTML] Epidemiological assessment of SARS-CoV-2 reinfection

M Almadhi, AS Alsayyad, R Conroy, S Atkin… - International Journal of …, 2022 - Elsevier
Objectives SARS-CoV-2 vaccination has been shown to reduce infection severity; however,
the reinfection frequency among unvaccinated, partially vaccinated, and fully vaccinated …

[HTML][HTML] Safety and immunogenicity of COVID-19 BBIBP-CorV vaccine in children 3–12 years old

…, A Alawadhi, A Jaradat, A Almarabheh, M AlMadhi… - Vaccines, 2022 - mdpi.com
Background and Objectives: In the current COVID-19 pandemic, children below the age of 12
could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community…

[HTML][HTML] The efficacy and safety of hydroxychloroquine in patients with COVID-19: a multicenter national retrospective cohort

A Abdulrahman, I AlSayed, M AlMadhi… - Infectious diseases and …, 2021 - Springer
Introduction Hydroxychloroquine (HCQ) is an antimalarial drug that received worldwide
news and media attention in the treatment of patients with coronavirus disease 2019 (COVID-19)…

Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination

M AlMadhi, A AlAwadhi, N Stevenson, K Greish… - MedRxiv, 2022 - medrxiv.org
Studies have shown increased immunogenicity from heterologous boosting. This study
specifically assessed boosting with Pfizer-BioNTech in Sputnik V vaccination regimens. …

The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort

A Abdulrahman, I AlSayed, M AlMadhi, J AlArayed… - medRxiv, 2020 - medrxiv.org
Background Hydroxychloroquine is an antimalarial drug that received worldwide news and
media attention in the treatment of COVID-19 patients. This drug was used based on its …

The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes.(preprint)

M AlMadhi, A Abdulrahman, A AlAwadhi, A Rabaan… - 2020 - pesquisa.bvsalud.org
The current COVID-19 pandemic has affected more than 22 million cases and caused
immense burdens on governments and healthcare systems worldwide. Since its emergence in …

[PDF][PDF] The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort

AAIASM AlMadhi, JAASJM Aesha, K Sharif - 2021 - repository.rcsi.com
Introduction: Hydroxychloroquine (HCQ) is an antimalarial drug that received worldwide
news and media attention in the treatment of patients with coronavirus disease 2019 (COVID-19)…

Is sickle cell disease a risk factor for severe COVID‐19 outcomes in hospitalized patients? A multicenter national retrospective cohort study

A Abdulrahman, M Wael, F AlAmmadi, Z Almosawi… - …, 2021 - Wiley Online Library
Introduction Studies that examine the association between sickle cell disease (SCD) and
COVID‐19 outcomes are lacking. This study aims to determine whether SCD is a risk factor for …